MENU CLOSE

News & Events

Home > Lynozyfic (linvoseltamab-gcpt): Another Breakthrough for Patients With Relapsed or Refractory Myeloma

Lynozyfic (linvoseltamab-gcpt): Another Breakthrough for Patients With Relapsed or Refractory Myeloma

People living with multiple myeloma often relapse after several lines of therapy. When this happens, it can feel like options are running out. The recent approval of Lynozyfic (linvoseltamab-gcpt) is an important step forward in expanding treatment option for patients.

Lynozyfic was approved in July 2025 for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy.[1] Here are some important details about Lynozyfic:

  • Lynozyfic is a bispecific antibody—a type of treatment that helps cells in your immune system find and attack myeloma cells.
  • Lynozyfic works in a way that’s similar to other bispecific treatments like Tecvayli and Elrexfio—they all target a protein called BCMA, which is found on myeloma cells. This makes it easier for the immune system to recognize and attack those cancer cells.
  • Bispecific antibodies like Lynozyfic are generally more accessible, because they don’t require the individualized manufacturing process or lengthy preparation time associated with CAR T-cell therapy.

A clinical trial with myeloma patients who had received at least four prior treatments showed that 70% of them responded to Lynozyfic treatment. Of these individuals:

  • Half of the patients responded within 1 month of treatment
  • For 70%, the response has continued for a year (see figure below).
Lynozific (linvoseltamab-gcpt) Trial Results Graphic 1

[1] Including a proteasome inhibitor (such as Velcade, Kyprolis, or Ninlaro), an immunomodulatory agent (such as Revlimid or Pomalyst), and an anti-CD38 monoclonal antibody (such as Darzalex or Sarclisa).

Lynozyfic is given through an intravenous infusion:

  • Treatment starts with two step-up doses, which are small doses that gradually increase
    • After each step-up dose, you’ll have to stay in the hospital for 24 hours to be monitored for side effects
  • After you’ve received the step-up doses, you’ll receive the standard dose once a week for a total of 12 doses without any hospital stay
  • After the first 12 full doses, you’ll receive one full dose every 2 weeks for 5 weeks
  • If you’re responding, your doctor may decide to drop your treatment to once every 4 weeks; if not, your treatment will continue on the every-2-weeks schedule

Like many myeloma treatments, Lynozyfic can cause side effects. The most common is cytokine release syndrome, which can cause fever, chills, or trouble breathing. If these signs occur, it’s important to report them to your care team right away.

Several options are available for avoiding or reducing side effects. Neurologic problems—in particular, immune effector cell-associated neurotoxicity syndrome (ICANS)—can also occur, but they are not as common as CRS.

Side effects and Symptoms - Lynozific

Because of the side effect risks, Lynozyfic is only available through a special safety program. If you receive Lynozyfic, you’ll be given a wallet card to remind you and your care providers of what to watch for.

If you’re a caregiver for a myeloma patient, make sure the patient carries their wallet card and watch the patient for symptoms. If any develop, report them to the care team right away.

As with any myeloma treatment, it’s important for you and your caregiver to have open conversations with your care team about whether Lynozyfic is a good fit. If you’ve already been through several treatments, Lynozyfic offers a new chance at controlling your myeloma.

Interested in learning more about Lynozyfic? Talk to an MMRF patient navigator at the Patient Navigation Center at 1.888.841.MMRF (Monday through Friday, 9:00 AM to 7:00 PM ET) or email patientnavigator@themmrf.org.

Additional Resources